Replies to post #120780 on Biotech Values

[mcbio]

SNY’s Lyxumia Hits Phase-3 Primary-Endpoint As Lantus Addend

Dew, any current thoughts on how Lyxumia stacks up to Victoza and Byetta/Bydureon? Was doing a bit more DD on Zealand Pharma (ZLDPF.PK) and Lyxumia is their key drug. About a $450M market cap on them; would be interesting to know what kind of royalties they are due from SNY on Lyxumia and if Lyxumia is otherwise well-positioned in the diabetes space relative to the competition.